Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy
O.-Y. Revach, A. M. Cicerchia, O. Shorer, B. Petrova, S. Anderson, J. Park, L. Chen, A. Mehta, S. J. Wright, N. McNamee, A. Tal-Mason, G. Cattaneo, P. Tiwari, H. Xie, J. M. Sweere, , K. Yizhak
This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.
bioRxiv · Feb 12, 2024 · PreprintCancer Biology